Allen Institute for Artificial Intelligence logo

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Ethanol and Acamprosate



Research Papers that Mention the Interaction

ResultsThe results showed that acamprosate attenuated the subjective craving induced by alcohol priming in comparison to placebo-treated patients.
Psychopharmacology  •  2009  |  View Paper
In vitro studies suggest that the excitotoxicity produced by ethanol can effectively be blocked by acamprosate.
CNS drugs  •  2005  |  View Paper
Acamprosate , a drug used during human alcohol detoxification, is able to completely block the glutamate increase observed during the first as well as the third withdrawal of ethanol.
Addictive behaviors  •  2004  |  View Paper
Currently, the best explanation for the effects of acamprosate seems to be that it inhibits the glutamatergic transmitter system involved in both the negative reinforcing effects of alcohol and the conditioned "pseudo-withdrawal" that may be important in cue-induced relapse.
The American journal on addictions  •  2003  |  View Paper
BACKGROUND Acamprosate has been found to enhance rates of complete abstinence and to increase percent days abstinent (PDA) from alcohol relative to placebo treatment.
Alcoholism, clinical and experimental research  •  2013  |  View Paper
Benzodiazepines, clomethiazole, tiagabine, vigabatrin, pregabalin, gabapentin, acamprosate , naltrexone, GHB, topiramate, ondansetron and baclofen at low dose (≤1 mg/kg, the dose range used in randomized trials in humans: 30 and 60 mg/day) have all been shown to at best reduce motivation to consume alcohol in rats.
Journal of psychopharmacology  •  2012  |  View Paper
For alcoholism, disulfiram, accamprosate , and naltrexone help prevent or limit reuse of alcohol.
The Indian journal of medical research  •  2012  |  View Paper
Preclinical studies indicate that acamprosate , a FDA approved drug for relapse prevention in detoxified alcoholic patients, reduces the glutamatergic hyperactivity triggered by ethanol withdrawal without depressing normal glutamatergic transmission.
European Neuropsychopharmacology  •  2008  |  View Paper
Recent studies in animals have suggested that acamprosate may have non-selective effects on craving for both alcohol and food.
Drug and alcohol dependence  •  2008  |  View Paper
Our results suggest that acamprosate may play a role in reduction of craving for alcohol after 6 weeks of treatment.
Addiction biology  •  2003  |  View Paper
Show More